Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laquinimod versus Avonex in relapsing-remitting multiple sclerosis
NL-OMON38727Phase 3Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jan 2014
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of laquinimod and interferon beta-1a in multiple sclerosis (MS) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Change in whole brain atrophy. Started Jan 2014; status: active, not recruiting.
02
Drugs
laquinimodinterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON38727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38727.